文献类型：期刊文献

英文题名：Incidence and predictors of in-stent restenosis following intervention for pulmonary vein stenosis due to fibrosing mediastinitis

作者：Jia, Mengfei[1];Su, Hongling[1];Jiang, Kaiyu[1];Wang, Aqian[1];Guo, Zhaoxia[1];Zhu, Hai[1];Zhang, Fu[1];Sun, Xuechun[2];Shi, Yiwei[3,4];Pan, Xin[5];Cao, Yunshan[2,3]

第一作者：Jia, Mengfei

通信作者：Cao, YS[1];Shi, YW[2];Cao, YS[2];Shi, YW[3];Pan, X[4]

机构：[1]Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou 730000, Peoples R China;[2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Heart Lung & Vessels Ctr, Chengdu 610072, Peoples R China;[3]NHC Key Lab Pneumoconiosis, 85 Jiefang South Rd, Taiyuan 030000, Peoples R China;[4]Shanxi Med Univ, Hosp 1, Dept Pulm & Crit Care Med, Shanxi Prov Key Lab Resp, Taiyuan 030000, Peoples R China;[5]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Cardiol, Shanghai 200030, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Heart Lung & Vessels Ctr, Chengdu 610072, Peoples R China;[2]corresponding author), NHC Key Lab Pneumoconiosis, 85 Jiefang South Rd, Taiyuan 030000, Peoples R China;[3]corresponding author), Shanxi Med Univ, Hosp 1, Dept Pulm & Crit Care Med, Shanxi Prov Key Lab Resp, Taiyuan 030000, Peoples R China;[4]corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Cardiol, Shanghai 200030, Peoples R China.

年份：2024

卷号：19

期号：1

外文期刊名：ORPHANET JOURNAL OF RARE DISEASES

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001330405300001)】；

基金：All individuals who contributed to this publication have been included as authors. This abstract has been accepted for presentation at the European Society of Cardiology Congress 2023 on August 26, 2023, in Amsterdam, the Netherlands.

语种：英文

外文关键词：Fibrosing mediastinitis; In-stent restenosis; Predictor; Pulmonary vein; Stenting

摘要：BackgroundFibrosing mediastinitis (FM) is a rare yet fatal condition, caused by different triggers and frequently culminating in the obstruction of the pulmonary vasculature and airways, often leading to pulmonary hypertension and right heart failure. Percutaneous transluminal pulmonary venoplasty (PTPV) is an emerging treatment for pulmonary vein stenosis (PVS) caused by FM. Our previous study showed as high as 24% of in-stent restenosis (ISR) in FM. However, the predictors of ISR are elusive.ObjectivesWe sought to identify the predictors of ISR in patients with PVS caused by extraluminal compression due to FM.MethodsWe retrospectively enrolled patients with PVS-FM who underwent PTPV between July 1, 2018, and December 31, 2022. According to ISR status, patients were divided into two groups: the ISR group and the non-ISR group. Baseline characteristics (demographics and lesions) and procedure-related information were abstracted from patient records and analyzed. Univariate and multivariate analyses were performed to determine the predictors of ISR.ResultsA total of 142 stents were implanted in 134 PVs of 65 patients with PVS-FM. Over a median follow-up of 6.6 (3.4-15.7) months, 61 of 134 PVs suffered from ISR. Multivariate analysis demonstrated a significantly lower risk of ISR in PVs with a larger reference vessel diameter (RVD) (odds ratio (OR): 0.79; 95% confidence interval [CI]: 0.64 to 0.98; P = 0.032), and stenosis of the corresponding pulmonary artery (Cor-PA) independently increased the risk of restenosis (OR: 3.41; 95% CI: 1.31 to 8.86; P = 0.012). The cumulative ISR was 6.3%, 21.4%, and 39.2% at the 3-, 6-, and 12-month follow-up, respectively.ConclusionISR is very high in PVS-FM, which is independently associated with RVD and Cor-PA stenosis.Trail RegistrationChinese Clinical Trials Register; No.: ChiCTR2000033153. URL: http://www.chictr.org.cn.